This statement outlines the strategic commitment of Huma Therapeutics Limited and its subsidiaries iPlato Healthcare Limited, iPlato Limited, eConsult Health Limited, Huma Therapeutics Inc and Alcedis GmbH (together, “Huma”) to ensure that modern slavery, human trafficking and forced labour are not present within our business operations or global supply chains.
This statement is made pursuant to Section 54(1) of the UK Modern Slavery Act 2015 (“MSA 2015”) for the financial year ending 31 December 2025 and has been approved by the Board of Directors.
Our operations and supply chain activities reflect continuous monitoring, and there have been no reported issues relating to modern slavery during this period.
First reporting year: our focus areas
This is Huma’s first modern slavery statement having met the statutory threshold under the MSA 2015. We are taking a pragmatic and proportionate approach to mitigating modern slavery and over the next 12 months we will continue to build on measures already in place whilst prioritising practical improvements in supplier due diligence, training and reporting. We will report transparently on our progress in our next statement.
Our commitment
Huma maintains a zero‐tolerance policy regarding modern slavery, human trafficking and any form of forced labour. As a global digital health technology company leveraging AI to assist the healthcare industry, we recognise our responsibility to embed proportionate systems to prevent, detect and address these risks across global jurisdictions.
Our business and supply chain
Huma is a global technology partner providing digital health solutions, including software development and data services for healthcare providers and pharmaceutical companies. We operate a hybrid workforce model supported by corporate presences in the UK, Germany and the United States. Our supply chain primarily comprises: (i) professional services, including sub‐consultants, software development partners, independent contractors and contingent workers; (ii) IT infrastructure, including SaaS providers, cloud hosting services and specialised healthcare technology hardware; and (iii) business operations support, including facilities management, office supplies and operational goods.
While we assess our inherent risk as low due to the professional and technical nature of our core business, we recognise that higher risks can emerge within multi-tier global hardware supply chains and third-party operational services.
We currently operate and procure in the United Kingdom, Europe, United States, and Middle East.
We will undertake proportionate mapping of first‐tier suppliers and selected higher‐risk second‐tier category suppliers during the next reporting period. We will use the outcomes to refine our risk assessment and disclosures.
Workforce due diligence and risk management
We apply and are strengthening a risk‐based approach to identify, mitigate, and safeguard against modern slavery and labour exploitation across three pillars.
Direct recruitment
All direct recruitment includes right‐to‐work or employment eligibility checks (including UK Right to Work and US Form I‐9), supplemented where applicable by background and criminal history checks. Our multi‐stage interview process supports voluntary employment and freedom to work and payroll audits are conducted to verify that employee bank details match the individual employed. We engage employees through transparent employment contracts and comply with applicable local minimum wage requirements and working time directives.
Contingent workers and suppliers
Contingent, agency and temporary workers are engaged either via preferred supplier partners who are contractually responsible for screening, vetting and employment eligibility verification or through freelance platforms where we perform the necessary verification and screening. All suppliers are vetted through our supplier assurance process and are engaged on supplier agreements requiring compliance with applicable laws.
We will during the next reporting period update our supplier agreement templates to incorporate clear modern slavery obligations and audit/cooperation language in addition to implementing business wide onboarding guidance for engagements via freelance platforms to ensure consistent screening and acceptance of our standards.
Huma will not enter into business with any organisation knowingly involved, or linked to, forced or indentured labour, servitude, human trafficking or illegal child labour.
Whistleblowing and safeguarding
We maintain an established Whistleblowing Policy to allow employees to raise concerns without fear of retaliation. Employees, contractors and suppliers are encouraged to report concerns confidentially to People@Huma.com.
Legal and regulatory alignment
We align our governance with key Modern Slavery standards including the UK Modern Slavery Act 2015, the US FAR 52.222‐50 (Combating Trafficking in Persons), the spirit of the California Transparency in Supply Chains Act, and the German Supply Chain Due Diligence Act (LkSG).
Training, accountability and measuring effectiveness
We will launch an updated global framework and annual modern slavery e‐learning module for all employees, with targeted content for Commercial, Technology, Clinical and Business Support. The framework will further train staff to define and spot forced labour, human trafficking, and exploitative practices within our global technology and hardware supply chains. We will also introduce KPI’s to evaluate the impact and strength of our anti-slavery framework and review feasibility before setting public targets. We further intend to provide suppliers with access to instructional resources to support alignment with our standards
Approval and sign‐off
This statement relates to the financial year ending 31 December 2025 and covers Huma Therapeutics Limited and its subsidiaries. It was approved by the Board of Directors with an effective date of 30 June 2026.
Signed
Dan Vahdat, CEO
Huma Therapeutics Limited